Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.96 USD
Change Today -0.71 / -6.65%
Volume 91.1K
CGIX On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $12.75
52 Week Low
12/3/14 - $4.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. The company offers microarray based testing, a microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer; and next generation sequencing testing, a proprietary next generation sequencing tests for the diagnosis and prognosis of genomic alterations in chronic lymphocytic leukemia, myeloma, and B-cell non-hodgkin's lymphomas. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutation analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides fluorescent in situ hybridization testing, an analysis of abnormalities at the chromosomal and gene levels; histology testing, a microscopic examination of stained tissue sections; and cytology testing, a non-gynecological fluid preparation for microscopic evaluations. Further, it offers IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various oncology-focused tests and laboratory services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. It also provides Expand Dx program for community hospital’s oncology diagnostic process; and consulting, guidance, and preparation of samples and clinical trial design. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

139 Employees
Last Reported Date: 03/16/15
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $260.3K
Vice President of Research & Development
Total Annual Compensation: $297.9K
Compensation as of Fiscal Year 2014.

cancer genetics inc (CGIX) Key Developments

Cancer Genetics, Inc. Signs Agreement with Harvard Pilgrim Healthcare

Cancer Genetics, Inc. announced that it has signed an agreement with Harvard Pilgrim Healthcare (HPHC). Under the terms of the agreement, CGI will offer cancer diagnostic services to individuals covered under Harvard Pilgrim plans. Harvard Pilgrim's extensive provider network includes over 135 hospitals and 28,000 doctors and clinicians among them, physicians who practice in a variety of settings, including individual practices, small medical groups and large multi-specialty groups. As part of the agreement, the HPHC network will have access to the full range of oncology-focused proprietary tests offered by CGI. Working with provider networks, such as Harvard Pilgrim Healthcare, is central to CGI's multi-part access and reimbursement strategy. By establishing relationships with leading payers and insurance companies, CGI plans to expand access to and ensure reimbursement for the company's genomic tests to help providers appropriately manage and personalize treatment.

Cancer Genetics, Inc. Appoints Rita Shaknovich as Medical Director and Vice President of Hematopathology Services

On July 1, 2015, Cancer Genetics, Inc. appointed Dr. Rita Shaknovich, age 48, as the Company's Medical Director and Vice President of Hematopathology Services, reporting directly to the Company's President and Chief Executive Officer. Dr. Shaknovich is a physician scientist and prior to joining the Company she was an Assistant Professor at Weill Cornell Medical College from April 2008 to June 2015.

Cancer Genetics Inc. Announces Partnership with Laboratory Services group to Offer Comprehensive Oncology Laboratory Testing and Solutions

Cancer Genetics, Inc. announced that it has entered into a partnership with the Laboratory Services group of ICON plc. The partnership will provide clients access to combined expertise ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics on a global basis. Oncology testing services are central to CGI's business model and are also a core focus area for ICON Laboratory Services. Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process: ICON's expertise in strategic development and in management and analysis of lab data from large-scale clinical programmes, and CGI's knowledge in applying genomics and other advanced technologies focused on cancer. The partnership is focused on providing a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $9.96 USD -0.71

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $21.94 USD +1.65
Genomic Health Inc $27.03 USD -0.05
NeoGenomics Inc $6.07 USD -0.04
Response Genetics Inc $0.12 USD -0.0045
Rosetta Genomics Ltd $3.01 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation CGIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at